Artificial Crab Burrows Facilitate Desalting of Rooted Mangrove Sediment in a Microcosm Study.

Water uptake by mangrove trees can result in salt accumulation in sedimentaround roots, negatively influencing growth. Tidal pumping facilitates salt release and canbe enhanced by crab burrows. Similarly, flushing of burrows by incoming tidal waterdecreases sediment salinity. In contrast to burrows with multiple entrances, the role of burrowswith one opening for salinity reduction is largely unknown. In a microcosm experiment westudied the effect of artificial, burrow-like macro-pores with one opening on the desalting ofmangrove sediment and growth of Rhizophora mangle L. seedlings. Sediment salinity,seedling leaf area and seedling growth were monitored over six months. Artificial burrowsfacilitated salt release from the sediment after six weeks, but seedling growth was notinfluenced. To test whether crab burrows with one opening facilitate salt release in mangroveforests, sediment salinities were measured in areas with and without R. mangle stilt roots inNorth Brazil at the beginning and end of the wet season. In addition, burrows of Ucidescordatus were counted. High crab burrow densities and sediment salinities were associated with stilt root occurrence. Precipitation and salt accumulation by tree roots seem to have alarger effect on sediment salinity than desalting by U. cordatus burrows

Mangrove Crab Ucides cordatus Removal Does Not Affect Sediment Parameters and Stipule Production in a One Year Experiment in Northern Brazil

Mangrove crabs influence ecosystem processes through bioturbation and/or litter feeding. In Brazilian mangroves, the abundant and commercially important crab Ucides cordatus is the main faunal modifier of microtopography establishing up to 2 m deep burrows. They process more than 70% of the leaf litter and propagule production, thus promoting microbial degradation of detritus and benefiting microbe-feeding fiddler crabs. The accelerated nutrient turn-over and increased sediment oxygenation mediated by U. cordatus may enhance mangrove tree growth. Such positive feed-back loop was tested in North Brazil through a one year crab removal experiment simulating increased harvesting rates in a mature Rhizophora mangle forest. Investigated response parameters were sediment salinity, organic matter content, CO2 efflux rates of the surface sediment, and reduction potential. We also determined stipule fall of the mangrove tree R. mangle as a proxy for tree growth. Three treatments were applied to twelve experimental plots (13 m × 13 m each): crab removal, disturbance control and control. Within one year, the number of U. cordatus burrows inside the four removal plots decreased on average to 52% of the initial number. Despite this distinct reduction in burrow density of this large bioturbator, none of the measured parameters differed between treatments. Instead, most parameters were clearly influenced by seasonal changes in precipitation. Hence, in the studied R. mangle forest, abiotic factors seem to be more important drivers of ecosystem processes than factors mediated by U. cordatus, at least within the studied timespan of one year

Extended biomass allometric equations for large mangrove trees from terrestrial LiDAR data

International audienceAccurately determining biomass of large trees is crucial for reliable biomass analyses in most tropical forests, but most allometric models calibration are deficient in large trees data. This issue is a major concern for high-biomass mangrove forests, especially when their role in the ecosystem carbon storage is considered. As an alternative to the fastidious cutting and weighing measurement approach, we explored a non-destructive terrestrial laser scanning approach to estimate the aboveground biomass of large mangroves (diameters reaching up to 125 cm). Because of buttresses in large trees, we propose a pixel-based analysis of the composite 2D flattened images, obtained from the successive thin segments of stem point-cloud data to estimate wood volume. Branches were considered as successive best-fitted primitive of conical frustums. The product of wood volume and height-decreasing wood density yielded biomass estimates. This approach was tested on 36 A. germinans trees in French Guiana, considering available biomass models from the same region as references. Our biomass estimates reached ca. 90% accuracy and a correlation of 0.99 with reference biomass values. Based on the results, new tree biomass model, which had R² of 0.99 and RSE of 87.6 kg of dry matter. This terrestrial LiDAR-based approach allows the estimates of large tree biomass to be tractable, and opens new opportunities to improve biomass estimates of tall mangroves. The method could also be tested and applied to other tree species

Analysis of floristic composition and structure of a tract of terra firme forest and of an adjacent mangrove stand on the Ajuruteua peninsula in Bragança, Pará

The current article provides data about floristic composition and forest structure of a terra firme forest fragment and a mangrove stand on Ajuruteua Peninsula, Bragança, Pará. The fragment is situated next to mangrove forest, without being exposed to tidal inundation. Compared to the mangrove, density and basal area are distinctly higher in terra firme forest (2320.0±736.1/417.7±349.6 indiv..ha-1; 25.2±11.0/9.1±5.3 m2.ha-1 for terra firme and mangrove forest, respectively). Three tree species form the mangrove forest, Rhizophora mangle, being the dominant species. Among the 40 families (71 species) found in terra firme, Arecaceae, Burseraceae (represented exclusively by Protium heptaphyllum) and Simaroubaceae (represented by Simarouba amara reach high importance values. Terra firme forest differs in species composition and complexity from restinga dune forest found in other parts of the peninsula. The high importance of palms in the terra firme forest could indicate influence of man in the past

Repositioning of the global epicentre of non-optimal cholesterol

High blood cholesterol is typically considered a feature of wealthy western countries(1,2). However, dietary and behavioural determinants of blood cholesterol are changing rapidly throughout the world(3) and countries are using lipid-lowering medications at varying rates. These changes can have distinct effects on the levels of high-density lipoprotein (HDL) cholesterol and non-HDL cholesterol, which have different effects on human health(4,5). However, the trends of HDL and non-HDL cholesterol levels over time have not been previously reported in a global analysis. Here we pooled 1,127 population-based studies that measured blood lipids in 102.6 million individuals aged 18 years and older to estimate trends from 1980 to 2018 in mean total, non-HDL and HDL cholesterol levels for 200 countries. Globally, there was little change in total or non-HDL cholesterol from 1980 to 2018. This was a net effect of increases in low- and middle-income countries, especially in east and southeast Asia, and decreases in high-income western countries, especially those in northwestern Europe, and in central and eastern Europe. As a result, countries with the highest level of non-HDL cholesterol-which is a marker of cardiovascular riskchanged from those in western Europe such as Belgium, Finland, Greenland, Iceland, Norway, Sweden, Switzerland and Malta in 1980 to those in Asia and the Pacific, such as Tokelau, Malaysia, The Philippines and Thailand. In 2017, high non-HDL cholesterol was responsible for an estimated 3.9 million (95% credible interval 3.7 million-4.2 million) worldwide deaths, half of which occurred in east, southeast and south Asia. The global repositioning of lipid-related risk, with non-optimal cholesterol shifting from a distinct feature of high-income countries in northwestern Europe, north America and Australasia to one that affects countries in east and southeast Asia and Oceania should motivate the use of population-based policies and personal interventions to improve nutrition and enhance access to treatment throughout the world.Peer reviewe

Height and body-mass index trajectories of school-aged children and adolescents from 1985 to 2019 in 200 countries and territories: a pooled analysis of 2181 population-based studies with 65 million participants

Summary Background Comparable global data on health and nutrition of school-aged children and adolescents are scarce. We aimed to estimate age trajectories and time trends in mean height and mean body-mass index (BMI), which measures weight gain beyond what is expected from height gain, for school-aged children and adolescents. Methods For this pooled analysis, we used a database of cardiometabolic risk factors collated by the Non-Communicable Disease Risk Factor Collaboration. We applied a Bayesian hierarchical model to estimate trends from 1985 to 2019 in mean height and mean BMI in 1-year age groups for ages 5–19 years. The model allowed for non-linear changes over time in mean height and mean BMI and for non-linear changes with age of children and adolescents, including periods of rapid growth during adolescence. Findings We pooled data from 2181 population-based studies, with measurements of height and weight in 65 million participants in 200 countries and territories. In 2019, we estimated a difference of 20 cm or higher in mean height of 19-year-old adolescents between countries with the tallest populations (the Netherlands, Montenegro, Estonia, and Bosnia and Herzegovina for boys; and the Netherlands, Montenegro, Denmark, and Iceland for girls) and those with the shortest populations (Timor-Leste, Laos, Solomon Islands, and Papua New Guinea for boys; and Guatemala, Bangladesh, Nepal, and Timor-Leste for girls). In the same year, the difference between the highest mean BMI (in Pacific island countries, Kuwait, Bahrain, The Bahamas, Chile, the USA, and New Zealand for both boys and girls and in South Africa for girls) and lowest mean BMI (in India, Bangladesh, Timor-Leste, Ethiopia, and Chad for boys and girls; and in Japan and Romania for girls) was approximately 9–10 kg/m2. In some countries, children aged 5 years started with healthier height or BMI than the global median and, in some cases, as healthy as the best performing countries, but they became progressively less healthy compared with their comparators as they grew older by not growing as tall (eg, boys in Austria and Barbados, and girls in Belgium and Puerto Rico) or gaining too much weight for their height (eg, girls and boys in Kuwait, Bahrain, Fiji, Jamaica, and Mexico; and girls in South Africa and New Zealand). In other countries, growing children overtook the height of their comparators (eg, Latvia, Czech Republic, Morocco, and Iran) or curbed their weight gain (eg, Italy, France, and Croatia) in late childhood and adolescence. When changes in both height and BMI were considered, girls in South Korea, Vietnam, Saudi Arabia, Turkey, and some central Asian countries (eg, Armenia and Azerbaijan), and boys in central and western Europe (eg, Portugal, Denmark, Poland, and Montenegro) had the healthiest changes in anthropometric status over the past 3·5 decades because, compared with children and adolescents in other countries, they had a much larger gain in height than they did in BMI. The unhealthiest changes—gaining too little height, too much weight for their height compared with children in other countries, or both—occurred in many countries in sub-Saharan Africa, New Zealand, and the USA for boys and girls; in Malaysia and some Pacific island nations for boys; and in Mexico for girls. Interpretation The height and BMI trajectories over age and time of school-aged children and adolescents are highly variable across countries, which indicates heterogeneous nutritional quality and lifelong health advantages and risks

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants.

BACKGROUND: Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. METHODS: We used data from 1990 to 2019 on people aged 30-79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. FINDINGS: The number of people aged 30-79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306-359) million women and 317 (292-344) million men in 1990 to 626 (584-668) million women and 652 (604-698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55-62) of women and 49% (46-52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43-51) of women and 38% (35-41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20-27) for women and 18% (16-21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. INTERPRETATION: Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings. FUNDING: WHO

Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants

Background Hypertension can be detected at the primary health-care level and low-cost treatments can effectively control hypertension. We aimed to measure the prevalence of hypertension and progress in its detection, treatment, and control from 1990 to 2019 for 200 countries and territories. Methods We used data from 1990 to 2019 on people aged 30-79 years from population-representative studies with measurement of blood pressure and data on blood pressure treatment. We defined hypertension as having systolic blood pressure 140 mm Hg or greater, diastolic blood pressure 90 mm Hg or greater, or taking medication for hypertension. We applied a Bayesian hierarchical model to estimate the prevalence of hypertension and the proportion of people with hypertension who had a previous diagnosis (detection), who were taking medication for hypertension (treatment), and whose hypertension was controlled to below 140/90 mm Hg (control). The model allowed for trends over time to be non-linear and to vary by age. Findings The number of people aged 30-79 years with hypertension doubled from 1990 to 2019, from 331 (95% credible interval 306-359) million women and 317 (292-344) million men in 1990 to 626 (584-668) million women and 652 (604-698) million men in 2019, despite stable global age-standardised prevalence. In 2019, age-standardised hypertension prevalence was lowest in Canada and Peru for both men and women; in Taiwan, South Korea, Japan, and some countries in western Europe including Switzerland, Spain, and the UK for women; and in several low-income and middle-income countries such as Eritrea, Bangladesh, Ethiopia, and Solomon Islands for men. Hypertension prevalence surpassed 50% for women in two countries and men in nine countries, in central and eastern Europe, central Asia, Oceania, and Latin America. Globally, 59% (55-62) of women and 49% (46-52) of men with hypertension reported a previous diagnosis of hypertension in 2019, and 47% (43-51) of women and 38% (35-41) of men were treated. Control rates among people with hypertension in 2019 were 23% (20-27) for women and 18% (16-21) for men. In 2019, treatment and control rates were highest in South Korea, Canada, and Iceland (treatment >70%; control >50%), followed by the USA, Costa Rica, Germany, Portugal, and Taiwan. Treatment rates were less than 25% for women and less than 20% for men in Nepal, Indonesia, and some countries in sub-Saharan Africa and Oceania. Control rates were below 10% for women and men in these countries and for men in some countries in north Africa, central and south Asia, and eastern Europe. Treatment and control rates have improved in most countries since 1990, but we found little change in most countries in sub-Saharan Africa and Oceania. Improvements were largest in high-income countries, central Europe, and some upper-middle-income and recently high-income countries including Costa Rica, Taiwan, Kazakhstan, South Africa, Brazil, Chile, Turkey, and Iran. Interpretation Improvements in the detection, treatment, and control of hypertension have varied substantially across countries, with some middle-income countries now outperforming most high-income nations. The dual approach of reducing hypertension prevalence through primary prevention and enhancing its treatment and control is achievable not only in high-income countries but also in low-income and middle-income settings. Copyright (C) 2021 World Health Organization; licensee Elsevier